Ann: Andover Delivers More Outstanding Lithium Results, page-140

I’d buy more at $1.80 - one more bad assay and that’s where we go, at which point SQM’s $2.31 offer will look like a distant memory, along with latest CR.

Share price ought to continue falling, as selloffs of this magnitude don’t tend to end until day 3. I expect a rebound on Wednesday.

But I doubt their bad luck will last, because other assays at TA2 could improve, and then there’s TA3 results (probably two months from now).

The MD has said they have perhaps 15 additional targets. If they heritage clear, they could drill them too.

So there are many opportunities to recover from this assumed TA2 failure. However, I’m veering on the side of caution until more assays comes to light. My SELL sentiment stays.